Peptide Profile
BPC-157
Body Protection Compound-157
01
Overview
Composition
Synthetic pentadecapeptide modeled after a segment of a protein naturally present in human gastric juice
Mechanism of Action
Promotes healing and regeneration across various tissues via angiogenesis promotion, modulation of growth factors, and anti-inflammatory actions
Primary Effects
Associated with wound-closure support, inflammatory-signal modulation, digestive-system protection, and a favorable safety profile in preclinical research
02
Discovery & Background
Initially identified and characterized in the early 1990s during investigations into gastric proteins
Researchers noted its capacity to enhance tissue repair and regeneration, leading to further exploration of its protective effects
Not FDA-approved for human therapeutic use by major regulatory bodies; remains primarily a research compound with uncontrolled user reports that cannot establish clinical benefit
03
Research Overview
The bulk of studies have been performed in animal models, reporting effects on wound closure, inflammatory signaling, and gastrointestinal injury models
- 01
Promotes angiogenesis, modulation of growth factors, and anti-inflammatory actions
- 02
Accelerates healing, reduces scar formation, stimulates new blood vessel growth
- 03
Strong anti-inflammatory properties for conditions involving chronic inflammation
- 04
Gastrointestinal injury models include ulcer and inflammatory-bowel-disease contexts, but human translation remains uncertain
- 05
Musculoskeletal and cartilage claims are largely preclinical or uncontrolled
- 06
Formal human clinical trials remain scarce and mostly limited to small pilot or retrospective analyses
Not approved for human therapeutic use; preclinical data and uncontrolled reports are not sufficient to establish clinical effectiveness
04
Safety Considerations
Monitoring
- Wound healing progress
- Inflammation markers
- Gastrointestinal symptoms
- Joint function and pain levels
- Overall tissue recovery
Side Effects
Local
- Transient redness or tenderness has been reported anecdotally
- Product purity and sterility are key uncertainties in non-approved preparations
Systemic
- Generally well-tolerated in reports
- Minimal adverse effects noted in preclinical studies
Contraindications
- Limited human safety data
- Caution advised without medical supervision
- Those with known sensitivities to peptides should proceed carefully
05
Educational Notice
BPC-157 has a broad preclinical literature for tissue repair, inflammation, and gastrointestinal injury models, but it lacks approval for human therapeutic use and controlled human data remain limited. Human benefit, safety, product quality, and long-term risk are not established. Clinical decisions require qualified medical oversight.
References
Research And Source List
Structured reference cards with source metadata and a direct link so users can inspect the original study/source.Pharmaceuticals | 2025
Recent review covering broad preclinical literature and the still-limited human evidence picture.Frontiers in Pharmacology | 2022
Source metadata available through the linked record.Frontiers in Pharmacology | 2021
Mechanistic and wound-healing review focused largely on preclinical work.Alternative Therapies in Health and Medicine | 2025
Two-person IV pilot reporting short-term tolerability only; not proof of efficacy or broad safety.Research source
Registered safety/pharmacokinetic study in healthy volunteers; posted results were not identified in the reviewed source set.Drugs@FDA
FDA search entry point for labeled products, approval documents, and regulatory status checks.FDA
FDA safety and regulatory context for selected bulk drug substances nominated for compounding, including several peptides.WADA
Current anti-doping source used for prohibited-in-sport review.Technical identity
Compound registry record supporting molecular identity fields.PubMed indexed literature query
Search results for indexed publications and abstracts related to BPC-157.Pattern Store